Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Proteomics International Laboratories Ltd. ( (AU:PIQ) ) has issued an announcement.
Proteomics International Laboratories Ltd responded to an ASX price query, clarifying that recent trading activity in its securities is likely due to several significant announcements. These include the US Medicare setting a reimbursement price for their PromarkerD test, which supports their US launch strategy, and new data on their OxiDx test indicating its potential to improve racehorse performance. The company has also achieved milestones such as clinical certification for its Australian diagnostics laboratory and initial sales of PromarkerD and PromarkerEso in Australia. These developments have likely contributed to increased investor interest.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.38 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd is a company operating in the biotechnology industry, focusing on precision diagnostic tests. Their primary products include the PromarkerD predictive test for diabetic kidney disease and the OxiDx oxidative stress biomarker test, with a market focus on enhancing healthcare outcomes and performance management in both human and veterinary applications.
Average Trading Volume: 319,762
Technical Sentiment Signal: Sell
Current Market Cap: A$66.31M
For detailed information about PIQ stock, go to TipRanks’ Stock Analysis page.